
<!doctype html>
<html lang="fr">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>PASO — Santé, biosecurity, expérimentation médicale et souveraineté sanitaire</title>
<meta name="description" content="Dossier PASO multilingue statique, prêt à soumission: souveraineté sanitaire, biosecurity, Kenya, Ghana, DRC/Ituri, Tuskegee, Guatemala, NSSM 200, Paperclip, Project Coast, données génétiques, pharmacovigilance, FDA, OMS, Africa CDC, ONU.">
<meta name="robots" content="index,follow,max-snippet:-1,max-image-preview:large">
<link rel="canonical" href="./dossier-health-biosecurity-medical-sovereignty-v4-static-multilingual.html">
<style>
:root{--bg:#f6f7f3;--ink:#14201d;--line:#dfe7df;--red:#991b1b;--green:#0f766e;--amber:#d97706;--blue:#155e75;--muted:#647067;--black:#111827}
*{box-sizing:border-box}body{font-family:Inter,system-ui,Segoe UI,Arial,sans-serif;margin:0;background:var(--bg);color:var(--ink);line-height:1.58}header{background:linear-gradient(135deg,#020617,#7f1d1d);color:white;padding:34px 20px;position:sticky;top:0;z-index:20}main{max-width:1320px;margin:auto;padding:22px}.topnav a{color:white;margin-right:10px;text-decoration:none;border:1px solid rgba(255,255,255,.25);border-radius:999px;padding:7px 10px;font-weight:800;font-size:13px;display:inline-block;margin-bottom:6px}h1{font-size:clamp(30px,5vw,58px);line-height:1.03;margin:12px 0}h2{font-size:clamp(22px,3vw,34px);line-height:1.15;margin:8px 0 12px}h3{margin:10px 0 8px}.card{background:white;border:1px solid var(--line);border-radius:20px;padding:18px;margin:0 0 16px;box-shadow:0 16px 40px rgba(15,23,42,.08)}.danger{border-left:8px solid #b91c1c}.amber{border-left:8px solid #d97706}.green{border-left:8px solid #0f766e}.blue{border-left:8px solid #155e75}.grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(280px,1fr));gap:14px}.twocol{display:grid;grid-template-columns:1.06fr .94fr;gap:18px}.button{display:inline-block;border-radius:12px;padding:10px 12px;background:#111827;color:white;text-decoration:none;border:0;margin:4px;font-weight:800}.button.light{background:#fff;color:#111827;border:1px solid #cbd5e1}.badge,.tag{display:inline-block;border-radius:999px;padding:5px 10px;font-size:12px;font-weight:800;margin:2px}.badge{background:#fee2e2;color:#991b1b;border:1px solid #fecaca}.tag{background:#ecfeff;color:#155e75;border:1px solid #a5f3fc}.small{color:#647067;font-size:13px}.force{font-size:18px;line-height:1.55}.scorebox{border-radius:16px;padding:16px;background:#111827;color:#fff}.scorebig{font-size:34px;font-weight:900;line-height:1}.scorelabel{font-size:12px;opacity:.8;text-transform:uppercase;letter-spacing:.04em}.note{background:#f8fafc;border:1px dashed #94a3b8;border-radius:16px;padding:14px}.list li{margin:7px 0}.kicker{letter-spacing:.05em;text-transform:uppercase;color:#991b1b;font-weight:800;font-size:12px}.src a{word-break:break-word}.radar-wrap,.viz{background:#fcfcfd;border:1px solid #e5e7eb;border-radius:20px;padding:12px;margin:12px 0}.langbar{display:flex;gap:6px;flex-wrap:wrap;margin-top:12px}.langbar button{border:1px solid rgba(255,255,255,.35);background:rgba(255,255,255,.12);color:white;border-radius:999px;padding:7px 10px;font-weight:900;cursor:pointer}.langbar button.active{background:white;color:#111827}.timeline{display:grid;gap:10px}.event{display:grid;grid-template-columns:100px 1fr;gap:10px;border:1px solid #e5e7eb;border-radius:14px;padding:10px;background:#fff}.event b{color:#7f1d1d}.pipe{display:flex;align-items:center;gap:8px;flex-wrap:wrap}.node{border-radius:14px;padding:10px 12px;background:#fff;border:1px solid #cbd5e1;font-weight:800}.arrow{font-weight:900;color:#7f1d1d}.mapgrid{display:grid;grid-template-columns:repeat(auto-fit,minmax(150px,1fr));gap:10px}.mapitem{border-radius:16px;border:1px solid #e5e7eb;background:white;padding:12px}.mapitem b{display:block;color:#7f1d1d}.cycle{display:grid;grid-template-columns:repeat(auto-fit,minmax(150px,1fr));gap:8px}.cycle div{border:1px solid #fecaca;background:#fff1f2;border-radius:16px;padding:10px;font-weight:800}.bars{display:grid;gap:10px;margin-top:14px}.barrow{display:grid;grid-template-columns:210px 1fr 50px;gap:8px;align-items:center}.bar{height:14px;background:#fee2e2;border-radius:999px;overflow:hidden}.bar span{display:block;height:100%;background:#b91c1c;border-radius:999px}.lang-section{display:block}body.js-enabled .lang-section{display:none}body.js-enabled .lang-section.active{display:block}@media(max-width:900px){header{position:static}.twocol{grid-template-columns:1fr}.event{grid-template-columns:1fr}.barrow{grid-template-columns:1fr}}@media print{header{position:static;background:white;color:#111827;border-bottom:2px solid #111827}.topnav,.button,.langbar{display:none!important}.card{box-shadow:none}body{background:white}body.js-enabled .lang-section{display:block}}
</style>
<script type="application/ld+json">
{"@context": "https://schema.org", "@type": "CreativeWork", "name": "PASO Health Biosecurity Medical Sovereignty Dossier", "creator": {"@type": "Organization", "name": "PASO / CSSP Mfuma"}, "inLanguage": ["fr", "en", "pt", "sw", "ln", "kg", "ha", "yo", "zu", "am", "ti", "wo", "nko"], "about": ["biosecurity", "health sovereignty", "medical ethics", "Tuskegee", "Guatemala", "NSSM 200", "Project Coast", "Kenya Ebola facility", "data sovereignty", "genomic data"]}
</script>
</head>
<body>
<header>
<div class="topnav"><a href="./index.html">Accueil</a><a href="./action-dossiers.html">Dossiers</a><a href="./dossier-us-kenya-health-biosecurity.html">Kenya case</a><a href="./publications.html">Publications</a><a href="./paso-resilience-transparency-retaliation-cost.html">Transparency standard</a></div>
<span class="badge">PASO-HEALTH-BIOSECURITY-006</span>
<h1>PASO — Health / Biosecurity / Medical Sovereignty</h1>
<p class="force">Static multilingual dossier: no empty JS shell. Full content is embedded directly in the HTML for browsers, print, crawlers and offline review.</p>
<p><a class="button" href="./dossier-health-biosecurity-medical-sovereignty-v4.json">JSON</a><a class="button light" href="./dossier-us-kenya-health-biosecurity.html">Kenya dossier</a><a class="button light" href="./action-dossiers.html">Dossiers</a></p>
<div class="langbar" id="langbar"><button type='button' data-lang='fr'>Français</button><button type='button' data-lang='en'>English</button><button type='button' data-lang='pt'>Português</button><button type='button' data-lang='sw'>Kiswahili</button><button type='button' data-lang='ln'>Lingala</button><button type='button' data-lang='kg'>Kikongo</button><button type='button' data-lang='ha'>Hausa</button><button type='button' data-lang='yo'>Yorùbá</button><button type='button' data-lang='zu'>Zulu</button><button type='button' data-lang='am'>አማርኛ</button><button type='button' data-lang='ti'>ትግርኛ</button><button type='button' data-lang='wo'>Wolof</button><button type='button' data-lang='nko'>N’Ko / Manding</button></div>
</header>
<main>

<article class="lang-section" data-lang="fr" id="lang-fr">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Français</div>
    <h1>États-Unis / Afrique — santé, biosecurity, expérimentation médicale et souveraineté sanitaire</h1>
    <p class="force">Version renforcée: rendre l’escalade coûteuse, pré-neutraliser la guerre narrative et rendre la transparence plus avantageuse que l’obstruction.</p>
    <p class="force">Seuil de saisine et d’action franchi: conservation des preuves, disclosure, audit biosécurité, données/échantillons, juridiction et piste de risque biologique élevé si dissimulation + dommage sont démontrés.</p>
    <p class="note">Version statique: le contenu complet est dans le HTML, même sans JavaScript. Les versions français, anglais et portugais sont les plus solides; les autres couches doivent être relues par locuteurs natifs avant dépôt formel.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Notation d’action</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Seuils objectifs</h3>
        <ul class="list"><li>Signal public: demande de documents et registre de sources</li><li>Conservation probatoire: contrats, logs, chaînes, métadonnées, données et échantillons</li><li>Audit formel: parlement, tribunal, Africa CDC/OMS et biosécurité indépendante</li><li>Action urgente: suspension, publication, fonds d’indemnisation, interdiction de transfert non audité</li><li>Risque maximal: dissimulation + dommage biologique + impossibilité de recours ou d’arrêt</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Narratif exécutif: ne pas confondre aide et contrôle</h2><p><b>Ce dossier est un instrument de risque, pas un jugement pénal final.</b> Il n’a pas besoin de prouver une confession secrète. Il demande si un pattern institutionnel documenté rend irrationnelle la confiance aveugle lorsque le même acteur demande accès aux données de santé africaines, données pathogènes, échantillons, informations génétiques, installations, patients, immunités juridiques et espace décisionnel.</p><p>Le danger n’est pas seulement l’expérimentation médicale directe. Le danger durable est l’érosion des capacités: les États africains deviennent dépendants de financements, laboratoires, analyses, produits médicaux, logistiques d’urgence, plateformes de données et cadres juridiques étrangers. Le pays peut posséder des bâtiments et perdre le commandement scientifique, juridique et économique de son propre système de santé.</p><p>Un partenariat sans réciprocité, juridiction locale, audit africain indépendant, indemnisation exécutoire, souveraineté sur les échantillons, souveraineté sur les données et accès égal n’est pas un partenariat de santé. C’est une architecture d’extraction en blouse blanche.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Cadre non accusatoire: faits, patterns et surface d’attaque</h2><p><b>Cette page ne demande pas aux institutions de condamner avant enquête.</b> Elle expose des faits, des patterns historiques, des réponses institutionnelles récurrentes et la surface d’attaque créée lorsque les systèmes de santé africains doivent compter sur une bonne foi non démontrée.</p><p>La théorie de dépôt est simple: la transparence est la voie la moins coûteuse. Si un partenariat sanitaire est propre, le partenaire peut publier les clauses, limiter les immunités, divulguer les règles sur données et échantillons, accepter la juridiction locale, financer l’indemnisation et permettre un audit africain indépendant. S’il répond par intimidation, secret, inversion médiatique, pression sur les tribunaux ou contournement exécutif, cette réaction devient une donnée du dossier.</p><p>Le dossier pré-enregistre donc l’espace de réponse prévisible: transparence complète, conformité partielle, vérité sélectionnée, guerre narrative, obstruction juridique, protection exécutive, verrouillage des données, pression sur l’hébergeur, pression cyber, intimidation ou escalade violente. PASO n’a pas besoin de deviner l’intention cachée; PASO enregistre le comportement choisi.</p></section><section class='card danger' id='retaliation-cost'><h2>Rendre l’escalade violente trop coûteuse: l’escalade devient preuve, pas solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>La voie la plus sûre pour tout acteur est la divulgation, la correction et l’audit indépendant. Toute réaction violente, coercitive ou clandestine doit devenir procéduralement coûteuse avant même d’apparaître. Cela ne demande pas de provocation. Cela demande un standard public: menaces, doxxing, intimidation, accidents suspects, pression sur hébergeurs, pression sur juges, suppression d’archives, refus d’accès, faux documents et harcèlement coordonné sont journalisés comme indicateurs de représailles.</p><p>Une escalade violente n’effacerait pas le dossier. Elle validerait la piste de risque maximal en montrant que l’acteur préfère la coercition à l’examen transparent. Le but n’est pas de provoquer la violence. Le but est de la rendre inutile, coûteuse, documentable et juridiquement pertinente.</p><p>La plateforme doit donc publier les règles de loyauté procédurale, mais garder internes les seuils exacts anti-gaming. Les acteurs hostiles doivent voir que la coopération baisse le risque. Ils ne doivent pas recevoir la carte complète des déclencheurs de score.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Pré-vaccination narrative: sauveur, pathologisation et piège anti-science</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>La réaction la plus probable n’est pas la violence ouverte. C’est la guerre narrative. La ligne prévisible sera de présenter les juges, communautés, syndicats et chercheurs africains qui demandent souveraineté des données, indemnisation, juridiction locale et contrôle des échantillons comme anti-science, anti-vaccins, conspirationnistes, autoritaires ou responsables d’un retard sanitaire.</p><p>Cette inversion doit être pré-neutralisée. Le dossier n’est pas anti-santé. Il est pro-disclosure, pro-pharmacovigilance, pro-capacité locale, pro-indemnisation, pro-production africaine, pro-souveraineté de laboratoire et pro-audit indépendant. La posture anti-science est celle qui demande aux populations d’accepter risque biologique, extraction de données et immunité sans preuve.</p><p>Le cadrage du sauveur doit aussi être nommé. Une puissance peut affaiblir les capacités médicales par sanctions, extraction, dépendance, contrôle de brevets, capture des données, opérations sécuritaires et pression exécutive, puis revenir comme sauveteur. L’Iran montre comment une pression géopolitique peut nuire à l’accès aux médicaments pendant que le langage humanitaire reste disponible. L’Afrique ne doit pas accepter un système où le même acteur affaiblit les capacités et vend le secours comme partenariat.</p></section><section class='card green' id='transparency-path'><h2>Voie de transparence: la seule sortie à faible risque</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>Le dossier doit rendre la collaboration moins coûteuse que l’obstruction. Un État, une entreprise, une fondation, un partenaire militaire ou une agence de santé peut réduire le risque en publiant les accords complets, acceptant l’audit africain, limitant les immunités, créant des fonds d’indemnisation, localisant la gouvernance des données, divulguant les règles d’échantillons et répondant au périmètre complet des questions.</p><p>Les réponses partielles ne réduisent que l’incertitude précise qu’elles résolvent. Elles n’effacent pas le pattern. Un document vrai mais sélectionné peut être utile, mais s’il omet catégories de patients, routes militaires, contractors, transferts d’échantillons, droits sur les données, indemnisation et juridiction, il devient une vérité sélectionnée, pas une clôture.</p><p>Le test est comportemental: les acteurs de bonne foi divulguent, réparent et acceptent la revue. Les acteurs de mauvaise foi pathologisent les questions, cachent les termes, pressent les tribunaux, invoquent des exceptions sécuritaires et attaquent les communautés.</p></section><section class='card blue' id='legal-escalation'><h2>Pistes de soumission: ONU, OMS/Africa CDC, UA, tribunaux et revue d’attaque biologique</h2><p>La première piste est la légalité sanitaire: divulgation, audit biosécurité, indemnisation, gouvernance données/échantillons, juridiction locale et suspension en attente de revue. Elle peut viser tribunaux nationaux, parlements, ministères de la santé, syndicats médicaux, Africa CDC, OMS et mécanismes africains des droits humains.</p><p>La deuxième piste est l’obstruction et la représaille: si des archives disparaissent, si les tribunaux sont pressés, si les hébergeurs sont intimidés ou si les critiques sont attaqués, ces actes doivent être journalisés séparément comme représailles, opacité et obstruction.</p><p>La troisième piste est la revue de risque maximal. Si des preuves crédibles montrent ensuite dissimulation plus dommage biologique plus impossibilité d’arrêter, auditer ou poursuivre, le dossier doit pouvoir escalader vers une revue d’attaque biologique ou de bio-terrorisme par les autorités compétentes. C’est une piste à seuil, pas un slogan.</p></section><section class='card blue' id='visuals'><h2>Tableau de bord visuel des risques</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Pattern temporel: événements récurrents et mémoire institutionnelle</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>La chronologie ne dit pas que chaque événement est identique. Elle montre une mémoire institutionnelle. Lorsqu’une bureaucratie apprend à traiter des populations vulnérables comme sources de données, terrains d’essai, systèmes d’alerte pathogène ou amortisseurs de risque, cette habitude peut passer du scandale à la procédure. Les noms changent; le pattern reste: extraire, nier, réduire l’excuse, protéger les opérateurs, réécrire le standard, continuer sous un nouveau programme.</p><p>Voilà pourquoi la bonne foi doit être démontrée, pas présumée. La question pertinente n’est pas le vocabulaire d’aide utilisé aujourd’hui. La question est de savoir si le contrat empêche structurellement la répétition du vieux pattern.</p></section><section class='card amber' id='space'><h2>Pattern spatial: le même risque se déplace entre peuples et territoires</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>Le pattern circule entre Afro-Américains, Guatemala, Puerto Rico, Haiti, Afrique australe, RDC, Kenya, Ghana et Zimbabwe. Il apparaît là où les populations ont moins de pouvoir de négociation, moins de ressources juridiques, une infrastructure médicale plus faible, une dépendance financière plus forte ou une capacité réduite à forcer la divulgation des documents.</p><p>Le Kenya est une illustration. Ghana et Zimbabwe montrent le problème des données et échantillons. RDC et Ituri posent le problème de la traçabilité des expositions. Project Coast montre le problème de sécurité biologique. Tuskegee et Guatemala montrent le non-consentement. Paperclip montre la protection des experts utiles.</p></section><section class='card danger' id='intent'><h2>L’intention peut se déduire de la politique, de la répétition et de la protection</h2><p>Un dossier recevable ne prétend pas lire les pensées. Il montre la répétition. En analyse institutionnelle, l’intention se déduit aussi de la continuation prévisible de conduites après avertissements, scandales, morts, décisions de justice, objections publiques ou exposition historique.</p><p>Lorsque l’exposition est suivie de secret, immunité, déplacement de juridiction, classification, protection d’experts utiles, refus de publier les contrats complets, refus de publier les droits sur les données, pression sur des États faibles ou pathologisation de la méfiance des communautés touchées, ces réponses ne sont pas neutres. Elles sont des mécanismes de protection. Un système qui rend la responsabilité plus difficile après exposition signale qu’il entend préserver la capacité de continuer, même s’il change de vocabulaire.</p><p>Ghana et Kenya comptent ici. Ghana a rejeté ou contesté des termes liés à l’accès aux données de santé sensibles et à la gouvernance. Le contentieux kényan et la protestation locale montrent le même seuil: la coopération sanitaire ne peut pas avancer comme diplomatie privée de l’exécutif lorsque du risque biologique public est transféré.</p></section><section class='card danger' id='data'><h2>Pourquoi faire confiance à l’accès aux données médicales et génétiques n’est pas rationnel dans ces conditions</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Les données médicales, pathogènes et génétiques ne sont pas de simples fichiers administratifs. Elles identifient vulnérabilités populationnelles, charge de maladie, profils immunitaires, circulation des pathogènes, failles thérapeutiques, géographies de faiblesse et valeur commerciale ou sécuritaire. Un acteur étranger qui y accède peut produire vaccins, diagnostics, brevets, modèles de ciblage, produits commerciaux, modèles IA de santé et évaluations de sécurité pendant que la population source ne reçoit aucun contrôle équivalent.</p><p>Dans des accords inégaux, les États africains peuvent fournir du renseignement biologique brut sans accès réciproque aux produits, codes sources, pipelines génomiques, propriété intellectuelle, logs d’incident, mécanismes de responsabilité et voies de recours. Le résultat est l’extraction scientifique: le pays devient terrain d’échantillons, pas puissance souveraine de recherche.</p><p>L’approbation FDA ou le statut réglementaire américain n’annule pas ce risque. Des produits approuvés par la FDA ont ensuite été retirés, restreints ou associés à des dommages massifs. L’approbation ne remplace pas pharmacovigilance locale, revue souveraine, indemnisation, signalement des effets indésirables, tests indépendants et responsabilité exécutoire.</p></section><section class='card amber' id='kenya'><h2>Cas Kenya: continuité moderne, pas controverse isolée</h2><p>Le cas Kenya n’est pas le centre de la doctrine; c’est un stress test vivant. Un centre Ebola soutenu par les États-Unis pour Américains exposés sur sol kényan soulève exactement les questions que l’histoire rend incontournables: pourquoi ces Américains sont-ils exposés? Que faisaient-ils en RDC/Ouganda? Quel rôle ont joué contractors, militaires, équipes de santé, diplomates ou ONG partenaires? Pourquoi le Kenya plutôt que des unités américaines ou européennes de bioconfinement? Qui contrôle le site? Qui a juridiction? Qui indemnise?</p><p>L’expérience Ebola plus faible du Kenya par rapport à la RDC ou l’Ouganda n’est pas un détail. Si un pays sans mémoire épidémique profonde accueille un risque venu d’ailleurs, la population peut porter le danger sans disposer des réflexes institutionnels, protections juridiques, confiance communautaire ou expérience clinique les plus solides.</p><p>Toute admission de patients exposés ou infectés avant disclosure complète, audit indépendant, juridiction locale, consultation communautaire et fonds d’indemnisation doit être traitée comme ligne rouge.</p></section><section class='card danger' id='drc'><h2>RDC, Ituri, peurs autour du SIDA et effets vaccinaux: auditer sans sur-affirmer</h2><p>Le dossier ne doit pas affirmer sans preuve que les États-Unis ont créé Ebola ou le SIDA. Cela affaiblirait la saisine. La position plus solide est que méfiance documentée, trajectoires d’exposition suspectes, effets secondaires inexpliqués, disclosure tardive, pharmacovigilance faible et contrôle étranger des données ou échantillons sont des déclencheurs d’audit.</p><p>En RDC et Ituri, conflit, pression foncière, mines, déplacements, violences armées et présence humanitaire/sécuritaire étrangère créent un environnement d’opacité élevée. Si des personnels ou contractors américains sont exposés dans ces zones, leur rôle, mandat, mouvements, échantillons, accès aux données, contacts et chaîne logistique doivent être divulgués aux autorités compétentes sous protection.</p><p>Les campagnes vaccinales suspectes et peurs d’effets indésirables doivent être traitées dans deux directions: les fausses rumeurs dangereuses doivent être corrigées car elles peuvent tuer soignants et patients; mais les inquiétudes légitimes ne doivent pas être méprisées lorsque l’histoire rend la méfiance prévisible. La réponse est pharmacovigilance indépendante, registre public d’effets indésirables, fonds d’indemnisation, accès local aux laboratoires et explication contrôlée par les communautés.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe et posture de négociation: la souveraineté des données n’est pas un problème d’attitude</h2><p>Le rejet par Ghana d’un accord de santé proposé par les États-Unis en raison de préoccupations sur l’accès aux données et la gouvernance n’est pas un désaccord mineur. Les rapports publics indiquent que l’accès aux données de santé sensibles était central et que la portée demandée dépassait ce qui serait normalement requis. Zimbabwe et Kenya apparaissent aussi dans des préoccupations similaires.</p><p>Si une délégation rapporte que le questionnement des termes américains a produit agressivité, pression ou entitlement du côté américain, PASO doit l’enregistrer comme signal de risque diplomatique seulement après obtention d’un affidavit, transcript, note officielle, compte rendu ou témoignage protégé. Le point vérifié publiquement suffit déjà: plusieurs États africains ont contesté ou rejeté des termes de santé parce que données, gouvernance, transparence et souveraineté étaient insuffisantes.</p><p>En diplomatie, une réaction agressive à des questions légitimes sur données, échantillons, confidentialité, réciprocité et juridiction n’est pas un détail. Cela suggère une pression extractive, pas un partenariat. Un vrai partenaire répond au périmètre. Un acteur contrôlant attaque la question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, pathogènes à base raciale et protection des chercheurs</h2><p>Project Coast compte parce qu’il prouve que biologie, racisme d’État, doctrine sécuritaire et infrastructure de recherche peuvent se rejoindre. Il montre pourquoi la souveraineté sanitaire africaine ne peut pas traiter la sécurité biologique comme un simple sujet de laboratoire. La biologie peut devenir instrument de gouvernance, intimidation, contrôle de fertilité, contre-insurrection ou tri populationnel.</p><p>La protection historique d’experts liés au nazisme par des programmes d’après-guerre et la protection ou responsabilité limitée de chercheurs dans des contextes sécuritaires controversés révèlent une habitude d’État: lorsque le savoir est utile, la responsabilité devient négociable. Cette habitude ne doit pas être importée dans les accords sanitaires africains.</p><p>La clause qui découle de cette histoire est simple: aucun programme biologique ou de santé étranger ne doit opérer sans divulgation des chercheurs, revue de conflits d’intérêt, divulgation des inconduites antérieures, limites échantillons/données, juridiction locale, droits d’audit et responsabilité personnelle.</p></section><section class='card danger' id='bioterror'><h2>Théorie de risque maximal: quand cela devient-il un dossier de bio-terrorisme ou d’attaque biologique?</h2><p>PASO ne doit pas employer le niveau maximal à la légère. Le seuil n’est pas la négligence ordinaire ou un mauvais contrat. Le seuil commence lorsque des preuves crédibles montrent usage intentionnel ou téméraire d’agents biologiques, données biologiques, routes d’exposition, dissimulation, expérimentation coercitive, ciblage populationnel ou prévention délibérée du remède d’une manière qui crée peur, maladie, mort, désorganisation sociale ou coercition politique.</p><p>Le dossier historique rend cette théorie recevable parce que des abus précédents ont émergé par documents tardifs, témoignages de victimes, enquêtes officielles, déclassification, procès, journalistes, commissions et lanceurs d’alerte. Dans chaque cas, le déni ou la minimisation publics ont précédé la confirmation. Cela ne prouve pas chaque allégation actuelle; cela prouve que le ridicule n’est pas une méthode scientifique.</p><p>Si des accords modernes cachent catégories de patients, transferts d’échantillons, données pathogènes, logs d’exposition, routes militaires, immunités et indemnisation tout en transférant du risque biologique sur territoire africain, le dossier doit conserver une piste de risque maximal. Au plus haut niveau, dissimulation soutenue + dommage biologique + impossibilité d’arrêter ou poursuivre peuvent devenir une théorie d’attaque biologique ou de bio-terrorisme à tester par les autorités compétentes.</p></section><section class='card danger' id='denial'><h2>Cycle de déni: pourquoi traiter toute critique comme conspiration fait partie du risque</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>Le cycle de déni est stable: dommage ou exposition; méfiance des victimes; réduction du problème; pathologisation des critiques; durcissement du cadre légal contre la responsabilité; excuse ou correction limitée; retour du programme sous nouveau langage.</p><p>Cela ne signifie pas que chaque rumeur est vraie. Cela signifie que le système n’a pas le droit d’utiliser l’existence de fausses rumeurs pour enterrer les demandes d’audit légitimes. La bonne réponse à la méfiance n’est pas la moquerie: c’est disclosure, test indépendant, contrôle local, indemnisation et juridiction exécutoire.</p></section><section class='card green' id='redlines'><h2>Lignes rouges et clauses requises</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Questions de dépôt pour tribunaux, parlements, ministères, OMS/Africa CDC et mécanismes UA</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Banque de sources: officielles, déclassifiées, historiques et actuelles</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="en" id="lang-en">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / English</div>
    <h1>United States / Africa — health, biosecurity, medical experimentation and health sovereignty</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="pt" id="lang-pt">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Português</div>
    <h1>Estados Unidos / África — saúde, biossegurança, experimentação médica e soberania sanitária</h1>
    <p class="force">Versão reforçada: tornar a escalada custosa, neutralizar previamente a guerra narrativa e tornar a transparência mais vantajosa que a obstrução.</p>
    <p class="force">Limiar de submissão e ação ultrapassado: preservação de provas, divulgação, auditoria de biossegurança, revisão de dados/amostras, jurisdição e pista de alto risco biológico se ocultação + dano forem demonstrados.</p>
    <p class="note">Versão estática: o conteúdo completo está no HTML mesmo sem JavaScript. Francês, inglês e português são as versões mais fortes; outras camadas precisam de revisão nativa antes de submissão formal.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Pontuação de ação</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Limiares objetivos</h3>
        <ul class="list"><li>Sinal público: pedido de documentos e registro de fontes</li><li>Preservação de provas: contratos, logs, cadeias, metadados, dados e amostras</li><li>Auditoria formal: parlamento, tribunal, Africa CDC/OMS e biossegurança independente</li><li>Ação urgente: suspensão, publicação, fundo de indenização, proibição de transferência não auditada</li><li>Risco máximo: ocultação + dano biológico + impossibilidade de reparação ou interrupção</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Narrativa executiva: não confundir ajuda com controle</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Enquadramento não acusatório: fatos, padrões e superfície de ataque</h2><p><b>Esta página não pede que instituições condenem antes de investigar.</b> Ela apresenta fatos, padrões históricos, respostas institucionais recorrentes e a superfície de ataque criada quando sistemas de saúde africanos são levados a confiar em boa-fé não demonstrada.</p><p>A teoria de submissão é simples: transparência é o caminho menos custoso. Se uma parceria sanitária é limpa, o parceiro pode publicar cláusulas, limitar imunidades, divulgar regras sobre dados e amostras, aceitar jurisdição local, financiar indenização e permitir auditoria africana independente. Se reage com intimidação, segredo, inversão midiática, pressão sobre tribunais ou contorno executivo, essa reação vira dado do dossiê.</p><p>O dossiê pré-registra o espaço previsível de resposta: transparência completa, conformidade parcial, verdade selecionada, guerra narrativa, obstrução jurídica, blindagem executiva, bloqueio de dados, pressão sobre hospedagem, pressão cibernética, intimidação ou escalada violenta. PASO não precisa adivinhar intenção oculta; registra o comportamento escolhido.</p></section><section class='card danger' id='retaliation-cost'><h2>Tornar a escalada violenta cara demais: a escalada vira prova, não solução</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>O canal mais seguro para todos é divulgação, correção e auditoria independente. Qualquer reação violenta, coercitiva ou clandestina deve tornar-se procedimentalmente cara antes de ocorrer. Isso não exige provocação. Exige padrão público: ameaças, doxxing, intimidação, acidentes suspeitos, pressão sobre hospedagem, pressão sobre juízes, eliminação de registros, recusa de acesso, documentos falsos e assédio coordenado são registrados como indicadores de retaliação.</p><p>Uma escalada violenta não apagaria o dossiê. Validaria a pista de risco máximo ao mostrar que o ator prefere coerção a revisão transparente. O objetivo não é provocar violência. É torná-la inútil, custosa, documentável e juridicamente relevante.</p><p>A plataforma deve publicar regras de justiça processual, mas manter internamente os limiares exatos anti-gaming. Atores hostis devem ver que cooperação reduz risco. Não devem receber o mapa completo dos gatilhos de pontuação.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Pré-vacinação narrativa: salvador, patologização e armadilha anti-ciência</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>A reação mais provável não é violência aberta. É guerra narrativa. A linha previsível será pintar juízes, comunidades, sindicatos e pesquisadores africanos que pedem soberania de dados, indenização, jurisdição local e controle de amostras como anti-ciência, antivacina, conspiracionistas, autoritários ou responsáveis por atrasos sanitários.</p><p>Essa inversão deve ser neutralizada antecipadamente. O dossiê não é anti-saúde. É pró-divulgação, pró-farmacovigilância, pró-capacidade local, pró-indenização, pró-produção africana, pró-soberania laboratorial e pró-auditoria independente. A posição anti-ciência é exigir que populações aceitem risco biológico, extração de dados e imunidade sem prova.</p><p>O enquadramento do salvador também deve ser nomeado. Uma potência pode enfraquecer capacidades médicas por sanções, extração, dependência, controle de patentes, captura de dados, operações de segurança e pressão executiva, depois retornar como salvadora. O Irã mostra como pressão geopolítica pode prejudicar acesso a medicamentos enquanto a linguagem humanitária continua disponível. África não deve aceitar um sistema em que o mesmo ator enfraquece capacidades e vende socorro como parceria.</p></section><section class='card green' id='transparency-path'><h2>Caminho de transparência: a única saída de baixo risco</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>O dossiê deve tornar colaboração mais barata que obstrução. Um Estado, empresa, fundação, parceiro militar ou agência de saúde pode reduzir risco publicando acordos completos, aceitando auditoria africana, limitando imunidades, criando fundos de indenização, localizando a governança de dados, divulgando regras de amostras e respondendo ao perímetro completo das perguntas.</p><p>Respostas parciais reduzem apenas a incerteza específica que resolvem. Não apagam o padrão. Um documento verdadeiro mas selecionado pode ser útil, mas se omite categorias de pacientes, rotas militares, contratados, transferências de amostras, direitos sobre dados, indenização e jurisdição, é verdade curada, não encerramento.</p><p>O teste é comportamental: atores de boa-fé divulgam, reparam e aceitam revisão. Atores de má-fé patologizam perguntas, escondem termos, pressionam tribunais, invocam exceções de segurança e atacam comunidades.</p></section><section class='card blue' id='legal-escalation'><h2>Trilhas de submissão: ONU, OMS/Africa CDC, UA, tribunais e revisão de ataque biológico</h2><p>A primeira trilha é legalidade sanitária: divulgação, auditoria de biossegurança, indenização, governança de dados/amostras, jurisdição local e suspensão até revisão. Pode ir a tribunais nacionais, parlamentos, ministérios da saúde, sindicatos médicos, Africa CDC, OMS e mecanismos africanos de direitos humanos.</p><p>A segunda trilha é obstrução e retaliação: se registros desaparecem, tribunais são pressionados, hospedagens são intimidadas ou críticos são atacados, esses atos devem ser registrados separadamente como retaliação, opacidade e obstrução.</p><p>A terceira trilha é revisão de risco máximo. Se provas críveis mostrarem ocultação mais dano biológico mais impossibilidade de parar, auditar ou processar, o dossiê deve poder escalar para revisão de ataque biológico ou bioterrorismo por autoridades competentes. É uma trilha de limiar, não um slogan.</p></section><section class='card blue' id='visuals'><h2>Painel visual de riscos</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Padrão temporal: eventos recorrentes e memória institucional</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Padrão espacial: o mesmo risco se desloca entre povos e territórios</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>A intenção pode ser inferida por política, repetição e blindagem</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Por que confiar no acesso a dados médicos e genéticos não é racional nestes termos</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Caso Quênia: continuidade moderna, não controvérsia isolada</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>RDC, Ituri, medos sobre AIDS e efeitos vacinais: auditar sem exagerar</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Gana, Zimbábue e postura de negociação: soberania dos dados não é problema de atitude</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, patógenos racializados e proteção de pesquisadores</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Teoria de risco máximo: quando isto vira dossiê de bioterrorismo ou ataque biológico?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Ciclo de negação: por que chamar tudo de conspiração faz parte do risco</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Linhas vermelhas e cláusulas exigidas</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Perguntas para tribunais, parlamentos, ministérios, OMS/Africa CDC e mecanismos da UA</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Banco de fontes: oficiais, desclassificadas, históricas e atuais</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="sw" id="lang-sw">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Kiswahili</div>
    <h1>Marekani / Afrika — afya, biosecurity, majaribio ya kitabibu na uhuru wa afya</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="ln" id="lang-ln">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Lingala</div>
    <h1>Etats-Unis / Afrika — bokolongono, biosecurity, ba expériences médicales mpe souveraineté sanitaire</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="kg" id="lang-kg">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Kikongo</div>
    <h1>Etats-Unis / Afrika — mavimpi, biosecurity, ba expériences médicales mpe souveraineté ya mavimpi</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="ha" id="lang-ha">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Hausa</div>
    <h1>Amurka / Afirka — lafiya, biosecurity, gwaje-gwajen likita da ikon lafiyar jama’a</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="yo" id="lang-yo">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Yorùbá</div>
    <h1>Amẹ́ríkà / Áfíríkà — ìlera, biosecurity, ìdánwò ìṣègùn àti òmìnira ìlera</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="zu" id="lang-zu">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Zulu</div>
    <h1>iMelika / i-Afrika — ezempilo, biosecurity, ukuhlolwa kwezokwelapha nobukhosi bezempilo</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="am" id="lang-am">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / አማርኛ</div>
    <h1>አሜሪካ / አፍሪካ — ጤና፣ biosecurity፣ የሕክምና ሙከራ እና የጤና ሉዓላዊነት</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="ti" id="lang-ti">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / ትግርኛ</div>
    <h1>ኣመሪካ / ኣፍሪቃ — ጥዕና፣ biosecurity፣ ሕክምናዊ ፈተነን ሉዓላዊነት ጥዕናን</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="wo" id="lang-wo">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / Wolof</div>
    <h1>Amerig / Afrig — wér-gi-yaram, biosecurity, jéem ci nit ak moom-sa-boppu wér-gi-yaram</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

<article class="lang-section" data-lang="nko" id="lang-nko">
  <section class="card danger">
    <div class="kicker">PASO-HEALTH-BIOSECURITY-006 / N’Ko / Manding</div>
    <h1>United States / Africa — health, biosecurity and medical-sovereignty risk</h1>
    <p class="force">Strengthened version: make escalation costly, pre-bunk narrative warfare and make transparency more advantageous than obstruction.</p>
    <p class="force">Filing and action threshold crossed: evidence preservation, disclosure, biosafety audit, data/sample review, jurisdiction and high biological-risk track if concealment plus harm are demonstrated.</p>
    <p class="note">Static version: full content is in the HTML even without JavaScript. French, English and Portuguese are strongest; other layers require native-speaker review before formal filing.</p>
  </section>
  <section class="card">
    <div class="twocol">
      <div>
        <h2>Action score</h2>
        <div class="grid">
          <div class="scorebox"><div class="scorelabel">Severity</div><div class="scorebig">97<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Public evidence</div><div class="scorebig">92<span style="font-size:18px">/100</span></div></div>
          <div class="scorebox"><div class="scorelabel">Action index</div><div class="scorebig">96<span style="font-size:18px">/100</span></div></div>
        </div>
        <h3>Objective thresholds</h3>
        <ul class="list"><li>Public signal: document request and source register</li><li>Evidence preservation: contracts, logs, chains, metadata, data and samples</li><li>Formal audit: parliament, court, Africa CDC/WHO and independent biosafety</li><li>Urgent action: suspension, publication, compensation fund, ban on unaudited transfer</li><li>Highest risk: concealment + biological harm + inability to obtain remedy or stop activity</li></ul>
      </div>
      <div class="radar-wrap">
        <h2>Composite risk map</h2>
        <div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div>
      </div>
    </div>
  </section>
  <section class='card danger' id='narrative'><h2>Executive narrative: do not confuse help with control</h2><p><b>This dossier is a risk instrument, not a final criminal judgment.</b> It does not need to prove a secret confession. It asks whether a documented institutional pattern makes blind trust irrational when the same actor requests access to African health data, pathogen data, samples, genomic information, facilities, patients, legal immunities and decision-making space.</p><p>The danger is not only direct medical experimentation. The more durable danger is capability erosion: African states become dependent on foreign funding, foreign laboratories, foreign analytics, foreign medical products, foreign emergency logistics, foreign data platforms and foreign legal frameworks. Once that happens, a country may possess buildings and equipment but lose command over the scientific, legal and economic meaning of its own health system.</p><p>A partnership that contains no reciprocity, no local jurisdiction, no independent African audit, no enforceable compensation, no sample sovereignty, no data sovereignty and no equal access is not a health partnership. It is an extraction architecture wearing a white coat.</p></section><section class='card green' id='nonjudgmental-intro'><h2>Non-judgmental filing frame: facts, patterns and attack surface</h2><p><b>This page does not ask institutions to convict before investigation.</b> It lays out facts, historical patterns, recurring institutional responses and the attack surface created when African health systems are asked to rely on undemonstrated good faith.</p><p>The filing theory is simple: transparency is the least costly path. If a health partnership is clean, the partner can publish clauses, limit immunities, disclose data and sample rules, accept local jurisdiction, fund compensation, and allow independent African audit. If the partner reacts with intimidation, secrecy, media inversion, pressure on courts, or executive bypass, that reaction becomes part of the risk record.</p><p>The dossier therefore pre-registers the predictable response space: full transparency, partial compliance, curated truth, narrative warfare, legal obstruction, executive shielding, data lockdown, host pressure, cyber pressure, intimidation, or violent escalation. PASO does not need to guess hidden intent; it records the chosen behavior.</p></section><section class='card danger' id='retaliation-cost'><h2>Make violent escalation too costly: escalation is evidence, not a solution</h2><div class='viz cycle'><div>1. Notice + source register</div><div>2. Transparency path open</div><div>3. Narrative inversion logged</div><div>4. Legal obstruction logged</div><div>5. Intimidation / violence logged</div><div>6. UN/AU/WHO escalation</div><div>7. Biological-risk review if harm + concealment</div></div><p>The safest channel for every actor is disclosure, correction and independent audit. Any violent, coercive or covert reaction should be made procedurally expensive before it occurs. This does not require provocation. It requires a published standard: threats, doxxing, intimidation, suspicious accidents, pressure on hosts, pressure on judges, deletion of records, denial of access, forged documents and coordinated harassment are logged as retaliation indicators.</p><p>A violent escalation would not erase the dossier. It would validate the highest-risk track by showing that the actor prefers coercion over transparent review. The goal is not to bait violence. The goal is to make violence useless, costly, documentable and legally relevant.</p><p>The platform should therefore publish only the fairness rules and keep exact anti-gaming thresholds internal. Hostile actors should see that cooperation lowers risk. They should not receive a complete map of the scoring triggers.</p></section><section class='card amber' id='narrative-warfare-prebunk'><h2>Narrative pre-vaccination: savior framing, pathologization and the anti-science trap</h2><div class='viz pipe'><span class='node'>Audit demand</span><span class='arrow'>→</span><span class='node'>“Anti-science” label</span><span class='arrow'>→</span><span class='node'>Court/community pressure</span><span class='arrow'>→</span><span class='node'>Disclosure avoided</span><span class='arrow'>→</span><span class='node'>Opacity penalty</span></div><p>The most likely reaction is not open violence. It is narrative warfare. The predictable line is: African judges, communities, unions and researchers who ask for data sovereignty, compensation, local jurisdiction and sample control will be framed as anti-science, anti-vaccine, conspiratorial, authoritarian, or responsible for public-health delay.</p><p>This inversion must be pre-bunked. The dossier is not anti-health. It is pro-disclosure, pro-pharmacovigilance, pro-local capacity, pro-compensation, pro-African manufacturing, pro-laboratory sovereignty and pro-independent audit. The anti-science position is the one that asks populations to accept biological risk, data extraction and immunity without evidence.</p><p>The savior frame also needs to be named. A power can harm medical capacity through sanctions, extraction, dependency, patent control, data capture, security operations and executive pressure, then return as a rescuer. Iran shows how geopolitical pressure can damage access to medicine while humanitarian language remains available. Africa should not accept a system where the same actor weakens capacity and sells rescue as partnership.</p></section><section class='card green' id='transparency-path'><h2>Transparency path: the only low-risk exit</h2><div class='viz pipe'><span class='node'>Full agreement</span><span class='arrow'>→</span><span class='node'>Sample/data rules</span><span class='arrow'>→</span><span class='node'>Local jurisdiction</span><span class='arrow'>→</span><span class='node'>Compensation fund</span><span class='arrow'>→</span><span class='node'>Risk reduction</span></div><p>The dossier should make collaboration cheaper than obstruction. A state, company, foundation, military partner or health agency can lower risk by publishing full agreements, accepting African audit, limiting immunities, creating compensation funds, localizing data governance, disclosing sample rules and answering the full perimeter of questions.</p><p>Partial answers reduce only the specific uncertainty they resolve. They do not erase the pattern. A true but selective document may be useful evidence, but if it omits patient categories, military routes, contractors, sample transfers, data rights, compensation and jurisdiction, it becomes curated truth rather than closure.</p><p>The test is behavioral: good-faith actors disclose, repair and accept review. Bad-faith actors pathologize questions, hide terms, pressure courts, invoke security exceptions and attack communities.</p></section><section class='card blue' id='legal-escalation'><h2>Submission track: UN, WHO/Africa CDC, AU, courts and biological-attack review</h2><p>The first track is public-health legality: disclosure, biosafety audit, compensation, data/sample governance, local jurisdiction and suspension pending review. This can go to national courts, parliaments, ministries of health, medical unions, Africa CDC, WHO and African human-rights mechanisms.</p><p>The second track is obstruction and retaliation: if records disappear, courts are pressured, hosts are intimidated, or critics are attacked, those actions should be logged separately as retaliation, opacity and obstruction.</p><p>The third track is highest-risk review. If credible evidence later shows concealment plus biological harm plus inability to stop, audit or prosecute, the dossier should be capable of escalation to biological-attack or bio-terrorism review by competent authorities. This is a threshold track, not a slogan.</p></section><section class='card blue' id='visuals'><h2>Visual risk dashboard</h2><div class='viz'><div class='grid'><div class='scorebox'><div class='scorelabel'>Data/sample sovereignty risk</div><div class='scorebig'>96/100</div></div><div class='scorebox'><div class='scorelabel'>Recurrence / pattern</div><div class='scorebig'>94/100</div></div><div class='scorebox'><div class='scorelabel'>Shielding / opacity</div><div class='scorebig'>93/100</div></div><div class='scorebox'><div class='scorelabel'>Remedy gap</div><div class='scorebig'>91/100</div></div></div><div class='bars'><div class='barrow'><b>Sample export</b><div class='bar'><span style='width:96%'></span></div><b>96</b></div><div class='barrow'><b>Genetic data capture</b><div class='bar'><span style='width:94%'></span></div><b>94</b></div><div class='barrow'><b>Immunity clauses</b><div class='bar'><span style='width:90%'></span></div><b>90</b></div><div class='barrow'><b>No compensation</b><div class='bar'><span style='width:92%'></span></div><b>92</b></div><div class='barrow'><b>FDA trust gap</b><div class='bar'><span style='width:84%'></span></div><b>84</b></div><div class='barrow'><b>Pathogen exposure opacity</b><div class='bar'><span style='width:89%'></span></div><b>89</b></div></div></div></section><section class='card danger' id='timeline'><h2>Time pattern: recurring events and institutional memory</h2><div class='viz timeline'><div class='event'><b>1932–1972</b><div><strong>Tuskegee</strong><br><span class='small'>United States / Black communities</span><p>Non-consent, racialized medical harm, delayed accountability</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 96</span></div></div><div class='event'><b>1946–1948</b><div><strong>STD experiments</strong><br><span class='small'>Guatemala</span><p>Vulnerable populations, infection/exposure without consent</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 95</span></div></div><div class='event'><b>1945–1950s</b><div><strong>Paperclip / JIOA</strong><br><span class='small'>U.S. / Europe</span><p>Useful experts shielded despite compromised records</p><span class='tag'>Severity 85</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>1974</b><div><strong>NSSM 200</strong><br><span class='small'>Global South</span><p>Population framed through U.S. security interests</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>1980s</b><div><strong>HIV risk stigma</strong><br><span class='small'>Haiti / U.S. health policy</span><p>A population pathologized as health threat</p><span class='tag'>Severity 80</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>1980s–1990s</b><div><strong>Project Coast</strong><br><span class='small'>Apartheid South Africa</span><p>CBW, race and fertility-linked research under security logic</p><span class='tag'>Severity 98</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>1999–2020s</b><div><strong>FDA-approved products later harmful</strong><br><span class='small'>U.S. / global pharma</span><p>Approval is not enough without recourse and pharmacovigilance</p><span class='tag'>Severity 78</span><span class='tag'>Evidence 92</span></div></div><div class='event'><b>2025</b><div><strong>America First Global Health Strategy</strong><br><span class='small'>U.S. global health doctrine</span><p>Health framed through U.S. interests and strategic access</p><span class='tag'>Severity 84</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2025–2026</b><div><strong>Data/specimen access disputes</strong><br><span class='small'>Africa / health agreements</span><p>Aid tied to data/pathogen access without equal reciprocity concerns</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 88</span></div></div><div class='event'><b>2026</b><div><strong>Rejection or contestation of U.S. terms</strong><br><span class='small'>Ghana / Zimbabwe / Kenya</span><p>Data sovereignty, governance, pathogen access, judicial disclosure</p><span class='tag'>Severity 92</span><span class='tag'>Evidence 90</span></div></div><div class='event'><b>2026</b><div><strong>Ebola centre for exposed Americans</strong><br><span class='small'>Kenya / DRC / Uganda</span><p>Externalized biological risk, military base, patient hierarchy, disclosure fight</p><span class='tag'>Severity 96</span><span class='tag'>Evidence 91</span></div></div><div class='event'><b>1953–present</b><div><strong>Sanctions, medicine access and industrial pressure</strong><br><span class='small'>Iran / West Asia</span><p>Political pressure damages medical access/capability while the actor still claims humanitarian concern</p><span class='tag'>Severity 86</span><span class='tag'>Evidence 82</span></div></div><div class='event'><b>2026+</b><div><strong>Narrative inversion risk</strong><br><span class='small'>Africa / digital and diplomatic space</span><p>Resistance to opaque health terms reframed as deadly misinformation or anti-science extremism</p><span class='tag'>Severity 91</span><span class='tag'>Evidence 78</span></div></div><div class='event'><b>Post-exposure pattern</b><div><strong>Disclosure resisted, then reframed</strong><br><span class='small'>International institutions</span><p>If transparency is refused after formal notice, opacity itself becomes a risk signal</p><span class='tag'>Severity 93</span><span class='tag'>Evidence 85</span></div></div></div><p>The timeline does not say every event is identical. It shows institutional memory. Once a bureaucracy learns to classify vulnerable populations as useful data sources, useful trial environments, useful pathogen-warning systems or useful risk buffers, that habit can migrate from scandal into procedure. The names change; the pattern remains: extract, deny, narrow the apology, shield the operators, rewrite the standard, continue under a new programme.</p><p>This is why good faith must be demonstrated, not assumed. The relevant question is not whether a modern official uses the vocabulary of aid. The relevant question is whether the contract structurally prevents repetition of the old pattern.</p></section><section class='card amber' id='space'><h2>Space pattern: the same risk moves across populations and territories</h2><div class='viz'><div class='mapgrid'><div class='mapitem'><b>United States</b>Tuskegee, FDA/product risk, policy command.</div><div class='mapitem'><b>Guatemala</b>STD experiments, non-consent, vulnerable populations.</div><div class='mapitem'><b>Puerto Rico / Haiti</b>Reproductive and stigma-risk precedents.</div><div class='mapitem'><b>Southern Africa</b>Project Coast, apartheid CBW, race/security biology.</div><div class='mapitem'><b>DRC / Ituri</b>Conflict, mining, exposure traceability, vaccine distrust.</div><div class='mapitem'><b>Kenya</b>Ebola facility, military base, court disclosure, protests.</div><div class='mapitem'><b>Ghana / Zimbabwe</b>Data/specimen governance resistance.</div></div></div><p>The pattern travels across Black America, Guatemala, Puerto Rico, Haiti, Southern Africa, DRC, Kenya, Ghana and Zimbabwe. It tends to appear where people have less bargaining power, fewer legal resources, weaker medical infrastructure, more dependency on foreign financing, or less ability to force discovery of documents.</p><p>Kenya is therefore an illustration. Ghana and Zimbabwe show that the data and specimen problem is broader. DRC and Ituri raise the exposure-traceability problem. Project Coast shows the biological-security problem. Tuskegee and Guatemala show the non-consent problem. Paperclip shows the shielding problem.</p></section><section class='card danger' id='intent'><h2>Intent can be inferred from policy, repetition and shielding</h2><p>A filing-grade dossier should not claim telepathy. It should show recurrence. Intent is not only a hidden mental state. In institutional risk analysis, intent is also inferred from the predictable continuation of conduct after warnings, scandals, deaths, court orders, public objections or historical exposure.</p><p>When exposure is followed by secrecy, immunity, jurisdiction shifting, classification, protection of useful experts, refusal to disclose full contracts, refusal to disclose data rights, pressure on weaker states, or pathologizing the distrust of affected communities, those responses are not neutral. They are shielding mechanisms. A system that makes accountability harder after being exposed signals that it intends to preserve the capacity to continue, even if it changes vocabulary.</p><p>This is where the Ghana and Kenya episodes matter. Ghana rejected or contested proposed terms over sensitive health-data access and governance. Kenya’s court process and local protest show the same threshold: health cooperation cannot proceed as private executive diplomacy when public biological risk is being transferred.</p></section><section class='card danger' id='data'><h2>Why trusting medical and genetic data access is not rational under these terms</h2><div class='viz pipe'><span class='node'>African patient/community</span><span class='arrow'>→</span><span class='node'>Sample / data / genome</span><span class='arrow'>→</span><span class='node'>Foreign analytics + IP</span><span class='arrow'>→</span><span class='node'>Products / patents / security models</span><span class='arrow'>→</span><span class='node'>No reciprocity / weak remedy</span></div><p>Medical data, pathogen data and genetic data are not ordinary administrative files. They identify population vulnerabilities, disease burden, immune profiles, pathogen circulation, treatment gaps, geographies of weakness, and possible commercial or security value. A foreign actor with access to that data can produce vaccines, diagnostics, patents, targeting models, commercial products, AI health models and security assessments while the population that generated the data receives no equivalent control.</p><p>Under unequal agreements, African states may provide raw biological intelligence while lacking reciprocal access to products, source code, genomic pipelines, intellectual property, incident logs, liability mechanisms, and litigation routes. The result is scientific extraction. The country becomes a sample field, not a sovereign research power.</p><p>FDA approval or U.S. regulatory status does not remove this risk. FDA-approved products have later been withdrawn, restricted or associated with large-scale harm. Approval is not a substitute for local pharmacovigilance, sovereign review, compensation, adverse-event reporting, independent testing, and enforceable liability.</p></section><section class='card amber' id='kenya'><h2>Kenya case: modern continuity, not isolated controversy</h2><p>The Kenya case is not the centre of the doctrine; it is a live stress test. A U.S.-backed Ebola facility for exposed Americans on Kenyan soil raises the exact questions the historical record makes unavoidable: Why are Americans exposed? What were they doing in DRC/Uganda? What role did contractors, military personnel, health teams, diplomatic teams or partner NGOs play? Why Kenya rather than U.S. or European biocontainment facilities? Who controls the site? Who has jurisdiction? Who is compensated if anything goes wrong?</p><p>Kenya’s weaker Ebola experience compared with DRC or Uganda is not a small detail. If a country without deep outbreak memory is asked to host risk from another region, the population may carry the danger without possessing the strongest institutional reflexes, legal protections, community trust, or clinical experience.</p><p>This is why any admission of exposed or infected patients before full disclosure, independent audit, local jurisdiction, community consultation and compensation funding must be treated as a red line.</p></section><section class='card danger' id='drc'><h2>DRC, Ituri, AIDS fears and vaccine-side-effect claims: audit without reckless overclaiming</h2><p>The dossier must not claim without proof that the United States created Ebola or AIDS. That would weaken the filing. The stronger position is that documented distrust, suspicious exposure pathways, unexplained side-effect claims, delayed disclosure, weak pharmacovigilance, and foreign control over data or samples are audit triggers.</p><p>In DRC and Ituri, conflict, land pressure, mining, displacement, armed violence and foreign humanitarian/security presence create a high-opacity environment. If American personnel or contractors are exposed in such zones, their role, mandate, movements, samples, data access, contacts and logistical chain must be disclosed to competent authorities under protection.</p><p>Suspicious vaccination campaigns and unexplained adverse-event fears must be handled in two directions at once: dangerous false rumours must be corrected because they can kill health workers and patients; but legitimate concerns must not be dismissed as irrational when the historical record makes distrust predictable. The solution is independent pharmacovigilance, public adverse-event registers, compensation funds, local laboratory access and community-controlled explanation.</p></section><section class='card amber' id='ghana'><h2>Ghana, Zimbabwe and negotiating posture: data sovereignty is not an attitude problem</h2><p>Ghana’s rejection of a proposed U.S. health deal over data access and governance concerns is not a minor diplomatic disagreement. Public reporting indicates that sensitive health-data access was a central issue, with concerns that the scope went beyond what would typically be required. Zimbabwe and Kenya were also reported in relation to similar data/specimen or agreement concerns.</p><p>If a delegation reports that questioning U.S. terms produced aggression, pressure or entitlement from the U.S. side, PASO should record that as a diplomatic-risk signal only after securing an affidavit, transcript, official note, meeting minutes or protected witness statement. The public-source verified point is already strong: several African states have challenged or rejected health terms because data, governance, transparency and sovereignty were insufficient.</p><p>In diplomacy, aggressive reaction to legitimate questions about data, samples, privacy, reciprocity and jurisdiction is not a small matter. It suggests extraction pressure, not partnership. A real partner answers the perimeter. A controlling actor attacks the question.</p></section><section class='card danger' id='apartheid'><h2>Apartheid, race-based pathogens and researcher shielding</h2><p>Project Coast matters because it proves that biology, state racism, security doctrine and research infrastructure can be joined. It also shows why African health sovereignty cannot treat biological security as a laboratory-only issue. Biology can become an instrument of governance, intimidation, fertility control, counterinsurgency, or population sorting.</p><p>The historical shielding of useful Nazi-linked experts through postwar programmes and the later protection or limited accountability of researchers in controversial security contexts reveal a recurrent state habit: when knowledge is useful, accountability becomes negotiable. That habit must not be imported into African health agreements.</p><p>The clause that follows from this history is simple: no foreign health or biological programme may operate without full researcher disclosure, conflict-of-interest review, prior misconduct disclosure, sample/data limits, local jurisdiction, audit rights and personal responsibility for violations.</p></section><section class='card danger' id='bioterror'><h2>Highest-risk theory: when does this become a bio-terrorism or biological-attack file?</h2><p>PASO should not use the highest label lightly. The threshold is not ordinary negligence or a bad contract. The threshold begins when credible evidence shows intentional or reckless use of biological agents, biological data, exposure routes, concealment, coercive experimentation, population targeting, or deliberate prevention of remedy in a way that creates fear, illness, death, social disruption or political coercion.</p><p>The historical record makes the theory receivable because previous abuses surfaced through delayed documents, victims’ testimony, official investigations, declassification, lawsuits, journalists, commissions and whistleblowers. In each case, public denial or minimization preceded confirmation. That does not prove every current allegation; it proves that dismissal by ridicule is not a scientific method.</p><p>If modern agreements hide patient categories, sample transfers, pathogen data, exposure logs, military routes, immunities and compensation while transferring biological risk onto African territory, the file must preserve a high-risk track. At the highest level, sustained concealment plus biological harm plus inability to stop or prosecute can become a biological-attack or bio-terrorism theory for competent authorities to test.</p></section><section class='card danger' id='denial'><h2>Denial cycle: why calling everything conspiracy is part of the risk</h2><div class='viz cycle'><div>1. Harm or exposure</div><div>2. Community distrust</div><div>3. Narrow denial</div><div>4. Critics pathologized</div><div>5. Immunity / secrecy</div><div>6. Limited apology</div><div>7. Programme returns renamed</div></div><p>The denial cycle has a stable shape: harm or exposure occurs; victims or communities distrust; authorities narrow the issue; critics are pathologized; the legal framework is tightened against accountability; a limited apology or technical correction is offered; the programme returns under new language.</p><p>This cycle does not mean every rumour is true. It means the system has no right to use the existence of false rumours to bury legitimate audit demands. The proper response to distrust is not mockery. It is disclosure, independent testing, local control, compensation and enforceable jurisdiction.</p></section><section class='card green' id='redlines'><h2>Red lines and required clauses</h2><ul class='list'><li>No admission of exposed or infected foreign patients on African soil before full publication of essential clauses and judicial/parliamentary review.</li><li>No transfer of samples, pathogen data, biological data, genomic sequences or metadata without consent, registry, purpose limitation, African control and audit.</li><li>No broad immunity covering gross negligence, contamination, death, concealment, non-consensual experimentation, data misuse or destruction of evidence.</li><li>No health aid conditioned on accepting foreign biological risk or surrendering pathogen/data sovereignty.</li><li>No FDA-approved or foreign-approved product deployment without local pharmacovigilance, adverse-event registry, liability, independent testing and compensation.</li><li>No health agreement that weakens the host country’s ability to manufacture, treat, test, audit, sue, compensate, publish and decide sovereignly.</li></ul></section><section class='card blue' id='questions'><h2>Filing questions for courts, parliaments, ministries, WHO/Africa CDC and AU mechanisms</h2><ul class='list'><li>Publish all health agreements, data-sharing agreements, pathogen-sharing terms, military-base terms, immunities, annexes and side letters.</li><li>Identify all patient categories, triage rules, admission rights, exclusion rules, evacuation routes and responsibility for exposed foreign personnel.</li><li>Disclose who controls samples, pathogen isolates, genomic sequences, metadata, analytical tools, AI models, storage systems and downstream products.</li><li>Prove reciprocity: what vaccines, diagnostics, treatments, patents, training, manufacturing rights and raw data return to the African state?</li><li>Create an escrow compensation fund before operation and define automatic compensation triggers.</li><li>Submit every high-risk facility to local judicial, parliamentary, community, medical-union and Africa CDC/WHO technical inspection.</li><li>Disclose all conflicts of interest, contractors, subcontractors, research partners, prior misconduct and legal immunities.</li><li>Create a public incident log: exposure, adverse event, leak, refusal, pressure, deleted data, missing document, diplomatic threat and correction.</li></ul></section><section class='card blue' id='sources'><h2>Source bank: official, declassified, historical and current</h2><ul class='src list'><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/us-kit-experts-arrive-kenya-ebola-facility-despite-court-order-protests-2026-06-03/' target='_blank' rel='noopener'>Reuters — U.S. kit and experts arrive in Kenya Ebola facility despite court order and protests</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/kenyas-president-defends-planned-us-backed-ebola-quarantine-facility-2026-06-02/' target='_blank' rel='noopener'>Reuters — Kenya court extends block and orders disclosure</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ruto-defends-us-backed-ebola-facility-kenya-right-thing-2026-06-04/' target='_blank' rel='noopener'>Reuters — Ruto defends U.S.-backed Ebola facility</a></li><li><span class='tag'>current</span> <a href='https://www.theguardian.com/world/2026/jun/04/experts-criticise-plan-for-american-only-ebola-quarantine-centre-in-kenya' target='_blank' rel='noopener'>The Guardian — experts criticise American-only Ebola quarantine centre in Kenya</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/united-states-and-kenya-sign-five-year-2-5-billion-health-cooperation-framework' target='_blank' rel='noopener'>U.S. State Department — U.S.-Kenya five-year $2.5B health cooperation framework</a></li><li><span class='tag'>current</span> <a href='https://www.health.go.ke/node/2144' target='_blank' rel='noopener'>Kenya Ministry of Health — Cooperation framework and data-sharing page</a></li><li><span class='tag'>current</span> <a href='https://apnews.com/article/f29f680cc017204de9269159f34b250d' target='_blank' rel='noopener'>AP — Ghana rejects proposed U.S. health deal over data privacy/governance concerns</a></li><li><span class='tag'>current</span> <a href='https://www.reuters.com/business/healthcare-pharmaceuticals/ghana-rejects-proposed-us-health-aid-deal-citing-data-concerns-source-says-2026-04-28/' target='_blank' rel='noopener'>Reuters — Ghana rejects proposed U.S. health aid deal, citing data concerns</a></li><li><span class='tag'>current</span> <a href='https://healthpolicy-watch.news/africa-stuck-between-global-pathogen-sharing-talks-and-conflicting-us-bilateral-agreements/' target='_blank' rel='noopener'>Health Policy Watch — Africa between pathogen-sharing talks and U.S. bilateral agreements</a></li><li><span class='tag'>current</span> <a href='https://www.thinkglobalhealth.org/article/tracking-the-america-first-bilateral-health-agreements' target='_blank' rel='noopener'>Think Global Health — Tracking America First bilateral health agreements</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/index.html' target='_blank' rel='noopener'>CDC — USPHS Untreated Syphilis Study at Tuskegee</a></li><li><span class='tag'>historical</span> <a href='https://www.cdc.gov/tuskegee/about/timeline.html' target='_blank' rel='noopener'>CDC — Tuskegee timeline</a></li><li><span class='tag'>historical</span> <a href='https://www.govinfo.gov/content/pkg/GOVPUB-PR-PURL-gpo15717/pdf/GOVPUB-PR-PURL-gpo15717.pdf' target='_blank' rel='noopener'>Presidential Commission — STD Research in Guatemala official report</a></li><li><span class='tag'>historical</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3828982/' target='_blank' rel='noopener'>American Journal of Public Health — Guatemala STD experiments</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76ve14p1/d121' target='_blank' rel='noopener'>FRUS — NSSM 200: population growth and U.S. security interests</a></li><li><span class='tag'>policy</span> <a href='https://www.nixonlibrary.gov/sites/default/files/virtuallibrary/documents/nssm/nssm_200.pdf' target='_blank' rel='noopener'>Nixon Library — NSSM 200 PDF</a></li><li><span class='tag'>policy</span> <a href='https://history.state.gov/historicaldocuments/frus1969-76v28/d17' target='_blank' rel='noopener'>FRUS — U.S. policy toward Southern Africa and material/political interests</a></li><li><span class='tag'>policy</span> <a href='https://www.cia.gov/readingroom/docs/CIA-RDP93T01142R000100210015-4.pdf' target='_blank' rel='noopener'>CIA Reading Room — United States Policy Toward Southern Africa</a></li><li><span class='tag'>policy</span> <a href='https://docs.house.gov/meetings/JU/JU10/20210217/111198/HHRG-117-JU10-20210217-SD013.pdf' target='_blank' rel='noopener'>House document exhibit — NSC-46 Black Africa and U.S. Black Movement</a></li><li><span class='tag'>shielding</span> <a href='https://www.archives.gov/iwg/declassified-records/rg-330-defense-secretary' target='_blank' rel='noopener'>National Archives — JIOA / Nazi War Crimes Disclosure Act records</a></li><li><span class='tag'>shielding</span> <a href='https://airandspace.si.edu/stories/editorial/project-paperclip-and-american-rocketry-after-world-war-ii' target='_blank' rel='noopener'>Smithsonian — Project Paperclip and American Rocketry after WWII</a></li><li><span class='tag'>cbw</span> <a href='https://unidir.org/publication/project-coast-apartheids-chemical-and-biological-warfare-programme/' target='_blank' rel='noopener'>UNIDIR — Project Coast: apartheid’s chemical and biological warfare programme</a></li><li><span class='tag'>cbw</span> <a href='https://digitallibrary.un.org/record/481899?ln=en' target='_blank' rel='noopener'>UN Digital Library — Project Coast record</a></li><li><span class='tag'>cbw</span> <a href='https://ora.ox.ac.uk/objects/uuid%3A79252e9a-46f2-459f-b406-4fb2a3c0b81a/files/m17595a068a233496688d64a0a7507252' target='_blank' rel='noopener'>Miles Jackson — Anti-Fertility Research in apartheid CBW Programme</a></li><li><span class='tag'>cbw</span> <a href='https://www.nonproliferation.org/wp-content/uploads/npr/73gould.pdf' target='_blank' rel='noopener'>Nonproliferation Review — South African Chemical and Biological Warfare Program overview</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/america-first-global-health-strategy' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy</a></li><li><span class='tag'>current</span> <a href='https://www.state.gov/wp-content/uploads/2025/09/America-First-Global-Health-Strategy-Report.pdf' target='_blank' rel='noopener'>U.S. State Department — America First Global Health Strategy report PDF</a></li><li><span class='tag'>drc</span> <a href='https://www.theguardian.com/global-development/2026/jun/03/drc-ebola-outbreak-could-have-begun-as-early-as-january-who-chief-says' target='_blank' rel='noopener'>Guardian — DRC Ebola outbreak could have begun earlier, WHO chief says</a></li><li><span class='tag'>drc</span> <a href='https://www.lemonde.fr/en/le-monde-africa/article/2026/05/27/some-congolese-believe-westerners-created-this-disease-in-the-drc-communities-mistrust-medical-workers-responding-to-the-ebola-virus-epidemic_6753853_124.html' target='_blank' rel='noopener'>Le Monde — DRC communities mistrust medical workers responding to Ebola</a></li><li><span class='tag'>drc</span> <a href='https://www.reuters.com/business/media-telecom/fake-rumors-real-killings-inside-congos-deadly-health-misinformation-crisis-2026-05-07/' target='_blank' rel='noopener'>Reuters — DRC deadly health misinformation crisis</a></li><li><span class='tag'>drc</span> <a href='https://healthpolicy-watch.news/drc-trains-rumour-busters-to-tackle-covid-misinformation/' target='_blank' rel='noopener'>Health Policy Watch — DRC rumour busters and vaccine hesitancy</a></li><li><span class='tag'>drc</span> <a href='https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1647147/full' target='_blank' rel='noopener'>Frontiers 2025 — DRC COVID-19 vaccine hesitancy scoping review</a></li><li><span class='tag'>drc</span> <a href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9247270/' target='_blank' rel='noopener'>PMC — DRC vaccine hesitancy and campaign delay after side-effect concerns</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-information' target='_blank' rel='noopener'>FDA — Vioxx withdrawal information</a></li><li><span class='tag'>fda</span> <a href='https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose' target='_blank' rel='noopener'>FDA — FDA and opioids: timeline of selected activities</a></li><li><span class='tag'>fda</span> <a href='https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm' target='_blank' rel='noopener'>CDC — Drug overdose deaths</a></li></ul></section>
</article>

</main>
<script>
document.body.classList.add("js-enabled");
function setLang(lang){
  document.querySelectorAll(".lang-section").forEach(function(el){el.classList.toggle("active", el.getAttribute("data-lang")===lang);});
  document.querySelectorAll(".langbar button").forEach(function(btn){btn.classList.toggle("active", btn.getAttribute("data-lang")===lang);});
  try{localStorage.setItem("paso_health_static_lang", lang);}catch(e){}
}
document.querySelectorAll(".langbar button").forEach(function(btn){btn.addEventListener("click", function(){setLang(btn.getAttribute("data-lang"));});});
setLang((function(){try{return localStorage.getItem("paso_health_static_lang") || "fr";}catch(e){return "fr";}})());
</script>
</body>
</html>
